Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the management of this previously untreatable neoplasm i...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
Series: | Indian Journal of Pathology and Microbiology |
Subjects: | |
Online Access: | http://www.ijpmonline.org/article.asp?issn=0377-4929;year=2013;volume=56;issue=3;spage=291;epage=293;aulast=Vij |
id |
doaj-70b480b7c3ca4e2f8b52eff5b93389e7 |
---|---|
record_format |
Article |
spelling |
doaj-70b480b7c3ca4e2f8b52eff5b93389e72020-11-24T22:36:42ZengWolters Kluwer Medknow PublicationsIndian Journal of Pathology and Microbiology0377-49292013-01-0156329129310.4103/0377-4929.120402Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinibMukul VijSusama PatraMohamed RelaGastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the management of this previously untreatable neoplasm into a treatable entity. Approximately 80% of advanced metastatic GISTs respond to imatinib treatment. However, the majority of patients suffer disease progression at a median of 2 years due to drug resistance. Generally progressing GISTs retain their typical morphology. Herein, we report an extremely rare case of progressive metastatic GIST with heterologous rhabdomyoblastic differentiation after, imatinib mesylate treatment. We also review the relevant literature.http://www.ijpmonline.org/article.asp?issn=0377-4929;year=2013;volume=56;issue=3;spage=291;epage=293;aulast=VijGastrointestinal stromal tumorimatinib mesylatemetastasisrhabdomyoblastic differentiation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mukul Vij Susama Patra Mohamed Rela |
spellingShingle |
Mukul Vij Susama Patra Mohamed Rela Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib Indian Journal of Pathology and Microbiology Gastrointestinal stromal tumor imatinib mesylate metastasis rhabdomyoblastic differentiation |
author_facet |
Mukul Vij Susama Patra Mohamed Rela |
author_sort |
Mukul Vij |
title |
Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib |
title_short |
Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib |
title_full |
Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib |
title_fullStr |
Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib |
title_full_unstemmed |
Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib |
title_sort |
hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib |
publisher |
Wolters Kluwer Medknow Publications |
series |
Indian Journal of Pathology and Microbiology |
issn |
0377-4929 |
publishDate |
2013-01-01 |
description |
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the management of this previously untreatable neoplasm into a treatable entity. Approximately 80% of advanced metastatic GISTs respond to imatinib treatment. However, the majority of patients suffer disease progression at a median of 2 years due to drug resistance. Generally progressing GISTs retain their typical morphology. Herein, we report an extremely rare case of progressive metastatic GIST with heterologous rhabdomyoblastic differentiation after, imatinib mesylate treatment. We also review the relevant literature. |
topic |
Gastrointestinal stromal tumor imatinib mesylate metastasis rhabdomyoblastic differentiation |
url |
http://www.ijpmonline.org/article.asp?issn=0377-4929;year=2013;volume=56;issue=3;spage=291;epage=293;aulast=Vij |
work_keys_str_mv |
AT mukulvij hepaticmetastasiswithheterologousrhabdomyoblasticdifferentiationinapatientwithgastrointestinalstromaltumortreatedwithimatinib AT susamapatra hepaticmetastasiswithheterologousrhabdomyoblasticdifferentiationinapatientwithgastrointestinalstromaltumortreatedwithimatinib AT mohamedrela hepaticmetastasiswithheterologousrhabdomyoblasticdifferentiationinapatientwithgastrointestinalstromaltumortreatedwithimatinib |
_version_ |
1725718598104645632 |